176.69

0.09% -0.16

Glaukos Corp (GKOS)

Overview News Price History Option Chain Financials Discussions Forecast

Glaukos Corp stock is traded at $176.69, with a volume of 885.34K. It is down -0.09% in the last 24 hours and up +10.53% over the past month. Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Previous Close:

$176.85

Open:

$176.72

24h Volume:

885.34K

Relative Volume:

1.03

Market Cap:

$10.42B

Revenue:

$551.35M

Net Income/Loss:

$-189.33M

P/E Ratio:

-53.68

EPS:

-3.2916

Net Cash Flow:

$-35.09M

1W Performance:

+6.70%

1M Performance:

+10.53%

6M Performance:

+45.24%

1Y Performance:

+130.58%

1-Day Range:

$174.21

$178.22

1-Week Range:

$164.09

$178.22

52-Week Range:

$73.16

$191.62

Glaukos Corp Stock (GKOS) Company Profile

Name

Glaukos Corp

Sector

Healthcare (1051)

Industry

Medical Devices (142)

Phone

949-367-9600

Address

1 GLAUKOS WAY, ALISO VIEJO, CA

Employee

1,094

Twitter

@GlaukosCorp

Next Earnings Date

2026-10-28

Latest SEC Filings

GKOS's Discussions on Twitter

Compare GKOS vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GKOS Glaukos Corp	176.69	10.42B	551.35M	-189.33M	-35.09M	-3.2916
ABT Abbott Laboratories	102.51	177.38B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	96.59	123.55B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	307.08	117.79B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	46.01	66.68B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	90.09	51.93B	6.30B	1.07B	1.09B	1.8406

Glaukos Corp Stock (GKOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-28-26	Initiated	UBS	Neutral
Jul-06-26	Initiated	H.C. Wainwright	Buy
Oct-27-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-01-25	Initiated	Goldman	Buy
May-01-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-19-25	Upgrade	Mizuho	Neutral → Outperform
Dec-11-24	Upgrade	Citigroup	Neutral → Buy
Dec-06-24	Initiated	UBS	Buy
Dec-02-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jul-10-24	Downgrade	Citigroup	Buy → Neutral
May-06-24	Upgrade	Jefferies	Hold → Buy
Dec-21-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight
Nov-28-23	Initiated	Truist	Buy
Nov-08-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-07-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-22-22	Initiated	Mizuho	Neutral
Dec-19-22	Upgrade	JP Morgan	Underweight → Neutral
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Oct-14-22	Resumed	Stephens	Overweight
Oct-04-22	Initiated	Needham	Buy
Jul-12-22	Upgrade	Stifel	Hold → Buy
Feb-03-22	Upgrade	William Blair	Mkt Perform → Outperform
Jan-19-22	Upgrade	Wells Fargo	Underweight → Equal Weight
Jan-18-22	Upgrade	BTIG Research	Neutral → Buy
Nov-03-21	Upgrade	Stephens	Equal-Weight → Overweight
Jul-26-21	Downgrade	Stephens	Overweight → Equal-Weight
Jul-20-21	Downgrade	Wells Fargo	Equal Weight → Underweight
Jul-14-21	Downgrade	Oppenheimer	Outperform → Perform
Jul-14-21	Downgrade	William Blair	Outperform → Mkt Perform
Apr-08-21	Upgrade	Oppenheimer	Perform → Outperform
Jan-29-21	Downgrade	Piper Sandler	Overweight → Neutral
Dec-16-20	Upgrade	Citigroup	Sell → Neutral
Dec-09-20	Initiated	Oppenheimer	Perform
Nov-17-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Oct-08-20	Downgrade	JP Morgan	Neutral → Underweight
Jun-15-20	Initiated	Jefferies	Hold
Mar-05-20	Initiated	Citigroup	Sell
Feb-28-20	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-20	Upgrade	Berenberg	Hold → Buy
Dec-12-19	Downgrade	Wells Fargo	Outperform → Underperform
Sep-30-19	Downgrade	BofA/Merrill	Buy → Underperform
Mar-08-19	Initiated	BTIG Research	Neutral
Aug-30-18	Initiated	Berenberg	Hold
Aug-29-18	Upgrade	JP Morgan	Neutral → Overweight
Aug-03-18	Reiterated	Stifel	Hold
Jun-21-18	Downgrade	JP Morgan	Overweight → Neutral
Apr-13-18	Downgrade	Stifel	Buy → Hold
Mar-01-18	Reiterated	Cantor Fitzgerald	Buy
Mar-02-17	Reiterated	Cantor Fitzgerald	Overweight
Jan-06-17	Upgrade	Stifel	Hold → Buy
Oct-27-16	Initiated	Wells Fargo	Outperform

View All

Glaukos Corp Stock (GKOS) Latest News

Oct 22, 2026

Glaukos Expands Retinal Pipeline With RevOpsis Deal - Orange County Business Journal

Oct 19, 2026

Forge’s Fierce Life Sciences Announces 2026 Fierce Innovation Awards Finalists and Unveils the Fierce Vanguard Gala - GlobeNewswire Inc.

Oct 19, 2026

Oct 17, 2026

Glaukos (NYSE:GKOS): High Growth Momentum Meets a Breakout Setup - ChartMill

Oct 17, 2026

Oct 16, 2026

Stifel reiterates Glaukos stock rating on strong iDose growth - Investing.com

Oct 16, 2026

Glaukos Corporation (GKOS) Reiterated at Buy by Stifel After Solid Q3 iDose Volume Diligence - StreetInsider

Oct 16, 2026

Oct 15, 2026

Mizuho lifts target for Glaukos stock to USD 190.00 - ad-hoc-news.de

Oct 15, 2026

Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery - Glance by Eyes On Eyecare

Oct 15, 2026

Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada

Oct 15, 2026

Glaukos Corporation (GKOS) Stock forecasts - Yahoo Finance UK

Oct 15, 2026

Oct 14, 2026

Glaukos Corporation (GKOS) Stock Forecasts - Yahoo Finance

Oct 14, 2026

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research

Oct 14, 2026

Midday Stock Roundup: loanDepot Shares Continue Falling - Orange County Business Journal

Oct 14, 2026

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research

Oct 14, 2026

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - TradingView

Oct 14, 2026

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Yahoo Finance

Oct 14, 2026

Oct 13, 2026

Glaukos reports positive 3-year, phase 3 Epioxa clinical outcomes - Glance by Eyes On Eyecare

Oct 13, 2026

Enrollment Complete in Glaukos Study of the PRESERFLO MicroShunt - Medical Product Outsourcing

Oct 13, 2026

Midday Stock Roundup: Karman Slips - Orange County Business Journal

Oct 13, 2026

Oct 12, 2026

GKOS Maintained by BTIG -- Price Target Raised to $205 - GuruFocus

Oct 12, 2026

(GKOS) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Oct 12, 2026

Oct 11, 2026

Glaukos: Steep Premium For New Therapies And Growth (NYSE:GKOS) - Seeking Alpha

Oct 11, 2026

Oct 10, 2026

Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada

Oct 10, 2026

Oct 09, 2026

Glaukos: The Second J-Code Rewrites The Risk Math - Seeking Alpha

Oct 09, 2026

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - The Globe and Mail

Oct 09, 2026

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Barchart.com

Oct 09, 2026